Table 1. Summary of clozapine trials and recorded measures.
| Clozapine trial | Start date | Time until neutropenia | Daily clozapine dose | Clozapine level (mg/dL) | Neutrophil nadir | Time to recovery | Other medications |
|---|---|---|---|---|---|---|---|
| 1 | July 2011 | 17 weeks | 300 mg | 0.17a | 0.41b | 19 days (spontaneous) | Quetiapine Valproate |
| 2 | Feb 2012 | 6 weeks | Not available | Not available | 0.53 | 20 days (spontaneous) | Lithium Olanzapine |
| 3 | Sep 2012 | 18 weeks | 400 mg | Not available | 0.40 | 1 day (GCS-F) (and clozapine trial continued for a further 7 months) | Topiramate Amisulpride GCS-F |
| 4 | Oct 2014 | Not available | 550 mg | 0.35 | Not available | Not available | Lithium |
GCS-F, granulocyte colony stimulating factor.
a
Clozapine level: 0.17 mg/dL is equivalent to 170 ng/mL.
b
Neutrophil nadir: 0.41×109/L is equivalent to 410/mm3 (cells).